Literature DB >> 15790306

Transcription factor therapeutics: long-shot or lodestone.

David Ghosh1, Athanasios G Papavassiliou.   

Abstract

Many drugs, both approved and in development, exert their effects through transcription factors. The complexity of the biology of transcriptional regulation, however, presents challenges to the effective design of therapies that directly target transcription factors. This review focuses on the different approaches that are currently pursued in therapeutics and drug discovery aimed at targeting transcription factors and signaling molecules, and their areas of effect in transcription factor biology. A relatively recent approach termed "transcription therapy" has been applied for a number of drugs in development, which may potentially provide a new avenue for targeting transcription factors for therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790306     DOI: 10.2174/0929867053202197

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  10 in total

Review 1.  Signatures of DNA target selectivity by ETS transcription factors.

Authors:  Gregory M K Poon; Hye Mi Kim
Journal:  Transcription       Date:  2017-03-16

Review 2.  Drugging the undruggable: transcription therapy for cancer.

Authors:  Chunhong Yan; Paul J Higgins
Journal:  Biochim Biophys Acta       Date:  2012-11-09

3.  Nrf2-miR-129-3p-mTOR Axis Controls an miRNA Regulatory Network Involved in HDACi-Induced Autophagy.

Authors:  Weijian Sun; Yongdong Yi; Guojun Xia; Yaxin Zhao; Yaojun Yu; Liyi Li; Chunya Hua; Bin He; Beng Yang; Chengyang Yu; Chenmin Ye; Fuyang Tu; Canjin Chen; Xiaoying Xu; Zhiqiang Zheng; Wenqian Wang; Xian Shen
Journal:  Mol Ther       Date:  2019-02-15       Impact factor: 11.454

4.  RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion.

Authors:  Rajeev K Boregowda; Oyenike O Olabisi; Walid Abushahba; Byeong-Seon Jeong; Keneshia K Haenssen; Wenjin Chen; Marina Chekmareva; Ahmed Lasfar; David J Foran; James S Goydos; Karine A Cohen-Solal
Journal:  Cancer Lett       Date:  2014-03-18       Impact factor: 8.679

5.  Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy.

Authors:  Veronica Albertini; Aklank Jain; Sara Vignati; Sara Napoli; Andrea Rinaldi; Ivo Kwee; Mohammad Nur-e-Alam; Julia Bergant; Francesco Bertoni; Giuseppina M Carbone; Jürgen Rohr; Carlo V Catapano
Journal:  Nucleic Acids Res       Date:  2006-03-29       Impact factor: 16.971

6.  Predicting DNA-binding sites of proteins from amino acid sequence.

Authors:  Changhui Yan; Michael Terribilini; Feihong Wu; Robert L Jernigan; Drena Dobbs; Vasant Honavar
Journal:  BMC Bioinformatics       Date:  2006-05-19       Impact factor: 3.169

7.  The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma.

Authors:  Rajeev K Boregowda; Daniel J Medina; Elke Markert; Michael A Bryan; Wenjin Chen; Suzie Chen; Anna Rabkin; Michael J Vido; Samuel I Gunderson; Marina Chekmareva; David J Foran; Ahmed Lasfar; James S Goydos; Karine A Cohen-Solal
Journal:  Oncotarget       Date:  2016-05-17

Review 8.  The regulatory role of AP-2β in monoaminergic neurotransmitter systems: insights on its signalling pathway, linked disorders and theragnostic potential.

Authors:  Mohamed H Al-Sabri; Maryam Nikpour; Laura E Clemensson; Misty M Attwood; Michael J Williams; Mathias Rask-Anderson; Jessica Mwinyi; Helgi B Schiöth
Journal:  Cell Biosci       Date:  2022-09-08       Impact factor: 9.584

Review 9.  In silico promoters: modelling of cis-regulatory context facilitates target predictio.

Authors:  Mauritz Venter; Louise Warnich
Journal:  J Cell Mol Med       Date:  2008-05-24       Impact factor: 5.310

Review 10.  Biophysical Techniques for Target Validation and Drug Discovery in Transcription-Targeted Therapy.

Authors:  Mehdi Moustaqil; Yann Gambin; Emma Sierecki
Journal:  Int J Mol Sci       Date:  2020-03-26       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.